Ten abstracts including 9 posters and 1 talk from the Swanson research lab have been accepted for presentation at the annual Soceity for NeuroOncology meeting in Washington D.C. Wide-ranging and novel results include clinically translational applications of patient-specific mathematical modeling using IDH-1, stem cell transplant therapy, radiation therapy optimization and predictive outcomes based on extent of surgery.

See selected abstracts in the special issue of Neuro-Oncology here

https://neuro-oncology.oxfordjournals.org/content/14/suppl_6.toc

New manuscript published in PLoS ONE (in press).

Discriminating time to progression and survival using a response metric tuned to patient-specific glioblastoma kinetics

Neal ML, Trister AD, Cloke T, Sodt R, Ahn S, Baldock AL, Bridge CA, Boone A, Rockne R, Swanson KR.

Accurate clinical assessment of a patient’s response to treatment for glioblastoma multiforme (GBM), the most malignant type of primary brain tumor, is undermined by the wide patient-to-patient variability in GBM dynamics and responsiveness to therapy. Using computational models that account for the unique geometry and kinetics of individual patients’ tumors, we developed a method for assessing response that discriminates progression-free and overall survival following therapy for GBM. Applying these models as untreated virtual controls, we generate a patient-specific “Days Gained” response metric that estimates the number of days a therapy delayed imageable tumor progression. We assessed treatment response in terms of Days Gained scores for 33 patients at the time of their first MRI scan following first-line radiation therapy. Based on Kaplan-Meier analyses, patients with significant treatment response (characterized by Days Gained scores of 100 or more) had improved progression-free survival and improved overall survival. Our results demonstrate that the Days Gained response metric calculated at the routinely acquired first post-radiation treatment time point provides prognostic information regarding progression and survival outcomes. Applied prospectively, our model-based approach has the potential to improve GBM treatment by accounting for patient-to-patient heterogeneity in GBM dynamics and responses to therapy.

Jacob Gile, Kellie Fontes, and Chantal Murthy presented their research at this year’s Undergraduate Research Symposium. Check out the pictures here.

Applying a patient-specific bio-mathematical model of glioma growth to develop virtual [18F]-FMISO-PET images

S Gu; G Chakraborty; K Champley; A M Alessio; J Claridge; R Rockne; M Muzi; K A Krohn; A M Spence; E C Alvord Jr; A R A Anderson; P E Kinahan; K R Swanson
Mathematical Medicine and Biology 2011

Read the article for free here:

Article DOI: 10.1093/imammb/dqr002

See Dr. Swanson’s presentation at this year’s American Association for Cancer Research (AACR) meeting in Orlando Florida

https://webcast.aacr.org/portal/p/2011annual/8110

The role of IDH1 mutated tumour cells in secondary glioblastomas:

an evolutionary game theoretical view

in Physical Biology, Vol 8, pp015016 (2011), has been downloaded 500 times so far.

This was achieved in 85 days from the date of publication. To put this into context, across all IOP journals 3% of articles were accessed over 500 times this year.

The article is free to read here:
https://stacks.iop.org/1478-3975/8/015016

Swanson lab publication, Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach has recently been published in the Journal of Physics in Medicine and Biology and is a featured article on medicalphysicsweb.org!